{"DataElement":{"publicId":"2691339","version":"2","preferredName":"Plasma Cell Disorder Transplantation Time Status Type","preferredDefinition":"A description of the plasma cell disorder status at transplant.","longName":"2688932v1.0:2688939v1.1","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2688932","version":"1","preferredName":"Plasma Cell Disorder Transplantation Time Status","preferredDefinition":"Specialized forms of antibody-producing B-LYMPHOCYTES. They synthesize and secrete immunoglobulin. They are found only in lymphoid organs and at sites of immune responses and normally do not circulate in the blood or lymph. (Rosen et al., Dictionary of Immunology, 1989, p169 & Abbas et al., Cellular and Molecular Immunology, 2d ed, p20)_Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._The grafting of tissues from one individual to another or place to place within a single individual._The continuum of experience in which events pass from the future through the present to the past._A condition or state at a particular time.","longName":"PLM_CL_DZ_TRN_ST","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2685344","version":"1","preferredName":"Plasma Cell Diseases and Disorders","preferredDefinition":"Specialized forms of antibody-producing B-LYMPHOCYTES. They synthesize and secrete immunoglobulin. They are found only in lymphoid organs and at sites of immune responses and normally do not circulate in the blood or lymph. (Rosen et al., Dictionary of Immunology, 1989, p169 & Abbas et al., Cellular and Molecular Immunology, 2d ed, p20):A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C12486:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasma Cell","conceptCode":"C12486","definition":"A fully mature B-Cell that produces a specific antibody.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BABCF9E-9CB5-6EE1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2674595","version":"1","preferredName":"Transplantation Time Status","preferredDefinition":"The grafting of tissues from one individual to another or place to place within a single individual.:the continuum of experience in which events pass from the future through the present to the past.:A condition or state at a particular time.","longName":"C15342:C25207:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Transplantation","conceptCode":"C15342","definition":"Transference of a tissue or organ within an individual, between individuals of the same species, or between individuals of different species.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Time","conceptCode":"C25207","definition":"The continuum of experience in which events pass from the future through the present to the past.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"384B648C-219F-1050-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-22","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-22","modifiedBy":"ONEDATA","dateModified":"2007-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C63AF-66D1-65EE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2688939","version":"1.1","preferredName":"Plasma Cell Disorder Status Type","preferredDefinition":"Specialized forms of antibody-producing B-LYMPHOCYTES. They synthesize and secrete immunoglobulin. They are found only in lymphoid organs and at sites of immune responses and normally do not circulate in the blood or lymph. (Rosen et al., Dictionary of Immunology, 1989, p169 & Abbas et al., Cellular and Molecular Immunology, 2d ed, p20)_Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A condition or state at a particular time._Something distinguishable as an identifiable class based on common qualities.","longName":"2688939v1.1","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Never treated","valueDescription":"Never Therapeutic Procedure","ValueMeaning":{"publicId":"2685077","version":"1","preferredName":"Never Therapeutic Procedure","longName":"2685077","preferredDefinition":"Not ever; at no time in the past (or future).: An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Never","conceptCode":"C70543","definition":"Not ever; at no time in the past (or future).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapeutic Procedure","conceptCode":"C49236","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter or stop a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B83BB14-A509-653C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-02","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2092EF2C-75F3-885E-E050-BB89AD43277B","beginDate":"2007-10-12","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"Complete Remission (CR)","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"2577915","version":"1","preferredName":"Complete Remission","longName":"2577915","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD68-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2092EF2C-75FD-885E-E050-BB89AD43277B","beginDate":"2007-10-12","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"Very Good Partial Response (VGPR)","valueDescription":"Very Good Partial Response (VGPR) of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2691332","version":"1","preferredName":"Very Good Partial Response (VGPR) of Multiple Myeloma or Plasma Cell Leukemia","longName":"2691332","preferredDefinition":"Very good partial response (VGPR) of multiple myeloma or plasma cell leukemia is characterized by serum and urine M-protein detectable by immunofixation but not on electrophoresis, or at least 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours.  Very good partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy very good partial response requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Very Good Partial Response of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70638","definition":"Very good partial response of multiple myeloma or plasma cell leukemia is characterized by serum and urine M-protein detectable by immunofixation but not on electrophoresis, or at least 90% reduction in serum M-protein and urine M-protein level < 100 mg/24 hours. Very good partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy very good partial response requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D3B8450-425D-6519-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-24","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2092EF2C-7607-885E-E050-BB89AD43277B","beginDate":"2007-10-24","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"Stable Disease (SD)","valueDescription":"Stable Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2691333","version":"1","preferredName":"Stable Multiple Myeloma or Plasma Cell Leukemia","longName":"2691333","preferredDefinition":"Stable multiple myeloma or plasma cell leukemia is characterized by not meeting the criteria for complete response, very good partial response, partial response or progression of disease. Stable disease requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stable disease requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stable Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70642","definition":"Stable multiple myeloma or plasma cell leukemia is characterized by not meeting the criteria for complete response, very good partial response, partial response or progression of disease. Stable disease requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stable disease requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D3B8450-4284-6519-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-24","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2092EF2C-7611-885E-E050-BB89AD43277B","beginDate":"2007-10-24","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"Stringent Complete Remission (sCR)","valueDescription":"Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2691334","version":"1","preferredName":"Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia","longName":"2691334","preferredDefinition":"Stringent complete response (sCR) of multiple myeloma or plasma cell leukemia is characterized by complete response plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence (confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the kappa/lamda ratio. An abnormal kappa/lambda ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an abnormal clone is kappa/lambda of > 4:1 or < 1:2.).  Stringent complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stringent complete response requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stringent Complete Response (sCR) of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70637","definition":"Stringent complete response (sCR) of multiple myeloma or plasma cell leukemia is characterized by complete response plus: normal free light chain ratio, and absence of clonal cells in the bone marrow by immunohistochemistry or immunofluorescence (confirmation with repeat bone marrow biopsy not needed). (Presence and/or absence of clonal cells is based upon the kappa/lambda ratio. An abnormal kappa/lambda ratio by immunohistochemistry and/or immunofluorescence requires a minimum of 100 plasma cells for analysis. An abnormal ratio reflecting the presence of an abnormal clone is kappa/lambda of > 4:1 or < 1:2.).  Stringent complete response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy stringent complete response requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D3B8450-42AB-6519-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-24","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2092EF2C-761B-885E-E050-BB89AD43277B","beginDate":"2007-10-24","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"Relapse from complete remission (untreated)","valueDescription":"Relapse from Complete Response of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2691335","version":"1","preferredName":"Relapse from Complete Response of Multiple Myeloma or Plasma Cell Leukemia","longName":"2691335","preferredDefinition":"Relapse from complete response of multiple myeloma or plasma cell leukemia requires one or more of the following: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of 5% or more plasma cells in the bone marrow (relapse from complete response has a 5% cutoff vs.10% for other categories of relapse); appearance of any other sign of progression (e.g., new plasmacytoma, lytic bone lesion, hypercalcemia). Relapse requires two consecutive assessments made at any time before classification as relapse, and/or the institution of any new therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Relapse from Complete Response of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70645","definition":"Relapse from complete response of multiple myeloma or plasma cell leukemia requires one or more of the following: reappearance of serum or urine M-protein by immunofixation or electrophoresis; development of 5% or more plasma cells in the bone marrow (relapse from complete response has a 5% cutoff vs.10% for other categories of relapse); appearance of any other sign of progression (e.g., new plasmacytoma, lytic bone lesion, hypercalcemia). Relapse requires two consecutive assessments made at any time before classification as relapse, and/or the institution of any new therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D3B8450-42D2-6519-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-24","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2092EF2C-7625-885E-E050-BB89AD43277B","beginDate":"2007-10-24","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"Progression","valueDescription":"Progression of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2691336","version":"1","preferredName":"Progression of Multiple Myeloma or Plasma Cell Leukemia","longName":"2691336","preferredDefinition":"Progression of multiple myeloma or plasma cell leukemia requires any one or more of the following: Increase of 25% or more from baseline in: serum M-component with an absolute increase 0.5 g/dL or more (for progressive disease, serum M-component increases of 1 g/dL or more are sufficient to define relapse if the starting M component is 5 g/dL or more); urine M-component with an absolute increase 200 mg. or more/ 24 hours; for recipients without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase more than 10 mg/dL); bone marrow plasma cell percentage (absolute percentage 10% or more); definite development of new bone lesions or soft tissue plasmacytomas, or definite increase in the size of any existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium more than 11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder. Progression of disease requires two consecutive assessments made at any time before classification as disease progression, and/or the institution of any new therapy.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Progression of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70643","definition":"Progression of multiple myeloma or plasma cell leukemia requires any one or more of the following: Increase of 25% or more from baseline in: serum M-component with an absolute increase 0.5 g/dL or more (for progressive disease, serum M-component increases of 1 g/dL or more are sufficient to define relapse if the starting M component is 5 g/dL or more); urine M-component with an absolute increase 200 mg. or more/ 24 hours; for recipients without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase more than 10 mg/dL); bone marrow plasma cell percentage (absolute percentage 10% or more); definite development of new bone lesions or soft tissue plasmacytomas, or definite increase in the size of any existing bone lesions or soft tissue plasmacytomas; development of hypercalcemia (corrected serum calcium more than 11.5 mg/dL or 2.65 mmol) that can be attributed solely to the plasma cell proliferative disorder. Progression of disease requires two consecutive assessments made at any time before classification as disease progression, and/or the institution of any new therapy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D3B8450-42F9-6519-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-24","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Removed and added back concept to update definition to latest NCIt. mc 11/11/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2092EF2C-762F-885E-E050-BB89AD43277B","beginDate":"2007-10-24","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"Partial Response (PR)","valueDescription":"Partial Response of Multiple Myeloma or Plasma Cell Leukemia","ValueMeaning":{"publicId":"2691337","version":"1","preferredName":"Partial Response of Multiple Myeloma or Plasma Cell Leukemia","longName":"2691337","preferredDefinition":"Partial response of multiple myeloma or plasma cell leukemia is characterized by a 50% or greater reduction in serum M-protein, and reduction in 24-hour urinary M-protein by 90% or more or to less than 200 mg/24 hours. If the serum and urine M-protein are unmeasurable (i.e., do not meet any of the following criteria: 1. serum M-protein at least 1 g/dL; 2. urine M-protein at least 200 mg/24 hours; a 50% or more decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria (provided the serum free light chain assay shows involved level at least 10 mg/dL and the serum free light chain is abnormal). If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, a 50% or more reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was 30% or more. In addition to the above listed criteria, a 50% or more reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. Partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy partial response requirements.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Partial Response of Multiple Myeloma or Plasma Cell Leukemia","conceptCode":"C70641","definition":"Partial response of multiple myeloma or plasma cell leukemia is characterized by a 50% or greater reduction in serum M-protein, and reduction in 24-hour urinary M-protein by 90% or more or to less than 200 mg/24 hours. If the serum and urine M-protein are unmeasurable (i.e., do not meet any of the following criteria: 1. serum M-protein at least 1 g/dL; 2. urine M-protein at least 200 mg/24 hours; a 50% or more decrease in the difference between involved and uninvolved free light chain levels is required in place of the M-protein criteria (provided the serum free light chain assay shows involved level at least 10 mg/dL and the serum free light chain is abnormal). If serum and urine M-protein are unmeasurable, and serum free light assay is also unmeasurable, a 50% or more reduction in plasma cells is required in place of M-protein, provided the baseline bone marrow plasma cell percentage was 30% or more. In addition to the above listed criteria, a 50% or more reduction in the size of soft tissue plasmacytomas is also required, if present at baseline. Partial response requires two consecutive assessments made at any time before the institution of any new therapy, and no known evidence of progressive or new bone lesions if radiographic studies were performed; radiographic studies are not required to satisfy partial response requirements.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3D3B8450-4320-6519-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-24","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-24","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":"Removed and then added the concept due to definition change in NCIt. mc 11/11/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2092EF2C-7639-885E-E050-BB89AD43277B","beginDate":"2007-10-24","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"},{"value":"unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"2575365","version":"1","preferredName":"Unknown","longName":"2575365","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-F372-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-15","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-01-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"2092EF2C-7643-885E-E050-BB89AD43277B","beginDate":"2009-09-29","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"ONEDATA","dateModified":"2015-09-25","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2688938","version":"1","preferredName":"Plasma Cell Diseases and Disorders Status Type","preferredDefinition":"Specialized forms of antibody-producing B-LYMPHOCYTES. They synthesize and secrete immunoglobulin. They are found only in lymphoid organs and at sites of immune responses and normally do not circulate in the blood or lymph. (Rosen et al., Dictionary of Immunology, 1989, p169 & Abbas et al., Cellular and Molecular Immunology, 2d ed, p20):A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.:A condition or state at a particular time.:Type; a subdivision of a particular kind of thing.","longName":"C12486:C2991:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Plasma Cell","conceptCode":"C12486","definition":"A fully mature B-Cell that produces a specific antibody.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3C4C63AF-66E9-65EE-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-12","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-12","modifiedBy":"ONEDATA","dateModified":"2007-10-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2092EF2C-75DC-885E-E050-BB89AD43277B","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"KUMMEROA","dateModified":"2021-02-23","changeDescription":".-2021-2-23 ak Ok to release per WZ.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"PerformedDiagnosis:diseaseStatusCode ","type":"HCT_BRIDG","context":"NHLBI"},{"name":"pre_ted_pcell_status_hsct","type":"NMDP_FN","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the plasma cell diso","type":"Preferred Question Text","description":"What was the plasma cell disorder status at transplantation?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2691339","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.diseaseStatusCode WHERE PerformedDiagnosis.value = {plasma cell disorder} AND PerformedDiagnosis > PerformedObservation.dateRange IS LESS THAN OR EQUAL TO PerformedSubstanceAdministration.dateRange AND PerformedSubstanceAdministration > DefinedSubstanceAdministration.nameCode = \"Administer Hematopoietic Cell Product {Transplantation}\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"2092EF2C-7698-885E-E050-BB89AD43277B","latestVersionIndicator":"Yes","beginDate":"2015-09-25","endDate":null,"createdBy":"NYCHM","dateCreated":"2015-09-25","modifiedBy":"KUMMEROA","dateModified":"2021-02-23","changeDescription":".-2021-2-23 ak Ok to release per WZ. System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}